COVID-19 the overwhelming potential pathology with those at highest risk to COVID-19 infection is uncontrolled activation of the immune system to combat infection, particularly overactivation of neutrophils. However, in the vulnerable, the action of these mediators lead to the destructive inflammation that can lead to overwhelming inflammation, leading to death. This outcome could be a result of the inflammatory response itself, or through the inability to fight off other respiratory bacterial of viral infections. Hence, a key element of timing, is to allow neutrophils to combat the virus, but not to induce overwhelming inflammation.
IRL201104 is not an approved or marketed drug or vaccine, but may potentially be a therapeutic approach that could be used preventatively to slow down ICU admissions if used at the right time. Immune Regulation are in touch with the relevant authorities concerning whether any investigational use of IRL201104 should be considered.
IRL201104 has been shown to quickly and markedly reduce lung infiltration of neutrophils in mice following bronchial challenge with lipopolysaccharide stimulating acute neutrophil activation. IRL1104 has a very short circulation exposure following IV administration and acts on neutrophil infiltration quickly but in a transient manner, which may mean that it would be able to provide a marked, but temporary, reduction in lung neutrophilia, potentially allowing the lung some respite from the high level of inflammation.
About Immune Regulation
Immune Regulation Limited is a clinical stage biotech company, pioneering new technologies for regulating and resetting the immune system and developing novel first-in-class therapies for inflammatory and immunological diseases.
Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects. Immune Regulation’s first-in-class immune resetting therapies have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system. These therapies exhibit short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.
At Immune Regulation our aim is to develop novel, safe and effective therapies that reset the immune system, transforming the lives of patients with inflammatory and immunological diseases.
Our statements may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this statement. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.
23 March 2020